Increase in Domestic and Overseas Revenue in the Chemicals Business
First written in FY2023-Q3. 4 of 10 entries say "Advanced", first in FY2025. Latest entry: 2026-08-06.
4 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「The chemicals business as a whole recorded higher revenue.」
The chemicals business recorded higher revenue in the first quarter under review, continuing the previous expansion in domestic and overseas sales. - FY2026AdvancedAnnual report
「Japan 18,935,129 3,895,773 22,830,903 Overseas 5,201,861 — 5,201,861 Revenue from contracts with customers 24,136,990 3,895,773 28,032,764」
Pharmaceutical business domestic sales were ¥18,935 million and overseas sales were ¥5,202 million, both up from the previous fiscal year. - FY2026-H1AdvancedAnnual report
「Japan 9,018,226 1,867,275 10,885,502 Overseas 2,403,896 — 2,403,896 Total 11,422,123 1,867,275 13,289,398」
In the pharmaceutical business, domestic sales were ¥9,018 million and overseas sales were ¥2,404 million, both up from the same period of the previous year. - FY2025AdvancedAnnual report
「Japan 16,954,742 3,725,453 20,680,196 Overseas 4,761,226 — 4,761,226 Revenue from contracts with customers 21,715,969 3,725,453 25,441,423」
Pharmaceutical business domestic sales were ¥16,955 million and overseas sales were ¥4,761 million, both up from the previous fiscal year. - FY2025-H1Both domestic and overseas sales upAnnual report
「Japan 8,505,885 1,780,331 10,286,217 Overseas 2,227,844 — 2,227,844 Total 10,733,730 1,780,331 12,514,062」
In the pharmaceutical business, domestic sales were ¥8,506 million and overseas sales were ¥2,228 million, both up from the same period of the previous year. - FY2024-Q3Both domestic and overseas sales downAnnual report
「Japan 11,051,497 3,021,517 14,073,014 Overseas 2,547,694 — 2,547,694 Total 13,599,192 3,021,517 16,620,709」
Pharmaceutical business revenue was ¥11,051 million in Japan and ¥2,548 million overseas, down in both markets from ¥12,554 million in Japan and ¥3,109 million overseas in the same period of the previous year. - FY2024-Q2Both domestic and overseas sales downAnnual report
「Japan 7,208,318 1,977,843 9,186,161 Overseas 1,618,051 — 1,618,051 Total 8,826,369 1,977,843 10,804,213」
Pharmaceutical business revenue was ¥7,208 million in Japan and ¥1,618 million overseas, down in both markets from ¥8,668 million in Japan and ¥2,281 million overseas in the same period of the previous year. - FY2024-Q1Both domestic and overseas sales downAnnual report
「Japan 3,674,134 1,004,636 4,678,770 Overseas 804,613 — 804,613 Total 4,478,748 1,004,636 5,483,384」
Pharmaceutical business revenue for the first quarter of the current fiscal year was ¥3,674 million in Japan and ¥805 million overseas, down in both markets from ¥4,537 million in Japan and ¥1,322 million overseas in the same quarter of the previous year. - FY2023Overseas sales up, domestic sales downAnnual report
「Principal geographical markets Japan 16,188,259 3,963,780 20,152,039 Overseas 3,910,811 — 3,910,811 Revenue from contracts with customers 20,099,071 3,963,780 24,062,851」
In the pharmaceutical business, overseas sales increased from the previous fiscal year to ¥3,911 million, while domestic sales decreased to ¥16,188 million. Domestic sales in the building materials business were ¥3,964 million. - FY2023-Q3First statedAnnual report
「Primary geographical markets: Japan 12,554,197 2,965,790 15,519,987; overseas 3,108,965 — 3,108,965; total 15,663,163 2,965,790 18,628,953.」
For the first 3 quarters, revenue by geographical market was disclosed as ¥12,554 million domestically and ¥3,109 million overseas for the Chemicals business, and ¥2,966 million domestically for the Building Materials business.